The CNS Paraneoplastic Syndrome: A Review of the Pathogenesis, Types, Manifestations and Diagnosis
Published: 2022-10-11
Page: 114-125
Issue: 2022 - Volume 5 [Issue 2]
Adedeji Okikiade *
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Edward Taylor
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Norhan Abdulrahman
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Oyeniyi Imoleayo
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Miriam Tikanide
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Aromedonghene Osharode
College of Medicine, All Saints University, Saint Vincent and the Grenadines.
Damisola Ogunesan
Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Paraneoplastic Neurological Syndromes (PNS) are a rare spectrum of non-metastatic manifestations likely secondary to T-cell or auto-antibodies induced neuronal dysfunction or cell death and are mostly associated with soft tissue cancers. PNS arises from either the cell membrane binding site of antineuronal antibodies causing protein dysfunction or from the antibodies that bind it to the intracellular antigens leading to necrosis of the cell. The neurological paraneoplastic phenotypes are numerous. Encephalomyelitis, acute cerebellar degeneration, Limbic Meningoencephalitis (LE), and dorsal sensory neuropathy are a few of them worth discussing. Specific antibodies are sometimes associated with specific underpinning tumor types. Screening for malignancy is important for all patients suspected of paraneoplastic neurological manifestations. Urgent biotherapy initiation is important in treating patients with the paraneoplastic neurological syndrome. It is more effective in cell surface antibodies than intracellular antibodies, as it removes the inexplicit tumor. This review article aims to elucidate the possible etiopathogenic patterns of different types of PNS.
Keywords: Cancer, paraneoplastic syndrome, paraneoplastic neurological syndrome, antibodies, limbic system, Opsoclonus-myoclonus, encephalitis
How to Cite
Downloads
References
Paraneoplastic Syndromes: Symptoms, Causes, Treatments & Tests. Cleveland Clinic, my.clevelandclinic.org/health/diseases/17938-paraneoplastic-syndromes.
Guichard MMA, Cabanne F, Tommasi M, Fayolle J. Polyneuropathies in cancer patients and paraneoplastic polyneuropathies. Lyon Medicale. 1956;41:309–29.
Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78:1363–68.
Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 Apr; 7(4):327-40.
DOI: 10.1016/S1474-4422(08)70060-7. PMID: 18339348; PMCID: PMC2367117.
Thapa B, Mahendraker N, Ramphul K. Paraneoplastic Syndromes. [Updated 2022 Jul 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Available:https://www.ncbi.nlm.nih.gov/books/NBK507890/.
Tanaka K. [Pathogenesis of paraneoplastic neurological syndromes]. Brain Nerve. 2010;62(4):309-18. Japanese. PMID: 20420170.
Erlich R, Morrison C, Kim B, Gilbert MR, Alrajab S. ANNA-2: An antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features—correlation of clinical improvement with tumour response. Cancer Invest. 2004;22:257–61
Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42:536–40.
Honnorat J, Viaccoz A. New concepts in paraneoplastic neurological syndromes. Rev Neurol (Paris). 2011;167(10):729-36.
DOI: 10.1016/j.neurol.2011.08.001. Epub 2011 Sep 3. PMID: 21890156.
Khan F, Kleppel H, Meara A. Paraneoplastic Musculoskeletal Syndromes. Rheum Dis Clin North Am. 2020;46(3):577-586.
DOI: 10.1016/j.rdc.2020.04.002. Epub 2020 Jun 7. PMID: 32631605.
“Paraneoplastic Neurologic Syndromes - NORD (National Organization for Rare Disorders).” NORD (National Organization for Rare Disorders), NORD; 2015. rarediseases.org/rare-diseases/paraneoplastic-neurologic-syndromes/
Zalewski NL, PittockS.J. (2019). Paraneoplastic Neurologic Disease. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham.
Available:https://doi.org/10.1007/978-3-030-16928-2_15
“Paraneoplastic Syndromes of the Nervous System - Symptoms and Causes.” Mayo Clinic; n2017.
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain. 2000;123:1481–94.
Viau M, Renaud MC, Grégoire J, Sebastianelli A, Plante M. Paraneoplastic syndromes associated with gynecological cancers: A systematic review. Gynecol Oncol. 2017;146(3):661-671.
DOI: 10.1016/j.ygyno.2017.06.025. Epub 2017 Jun 24. PMID: 28655412
Dalmau, Josep. “Paraneoplastic Neurologic Syndromes - NORD (National Organization for Rare Disorders).” NORD (National Organization for Rare Disorders), NORD; 2016.
Available:https://rarediseases.org/rare-diseases/paraneoplastic-neurologic-syndromes/
Graus, Francesc, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology - Neuroimmunology Neuroinflammation, 2021;8.
Available:https://nn.neurology.org/content/8/4/e1014,10.1212/NXI.0000000000001014 Available:https://nn.neurology.org/content/8/4/e1014
Zerr I, et al. "Detection of 14-3-3 Protein in the Cerebrospinal Fluid Supports the Diagnosis of Creutzfeldt-Jakob Disease." Annals of Neurology. 1998;43(1):32–40,
Available:pubmed.ncbi.nlm.nih.gov/9450766/, 10.1002/ana.410430109. Accessed 27 July 2022.
Saiz A, Graus F, Dalmau J, Pifarre A, Marin C, Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol. 1999;46:774–77.
Grisold W, Giometto B, Vitaliani R, Oberndorfer S. Current approaches to the treatment of paraneoplastic encephalitis. Ther Adv Neurol Disord. 2011;4(4) :237-48.
Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838-54.
Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol. 2013;14(4):528-38.
DOI: 10.1007/s11864-013-0249-1. PMID: 23900965; PMCID: PMC3844017.
Wiwanitkit V. Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist. 2014;4(1):5.
DOI: 10.1177/1941874413509633. PMID: 24381703; PMCID: PMC3869311.